Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06932809 · ClinicalTrials.gov registry record · Early Phase 1

Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A

A Early Phase 1 study of Tauopathies, sponsored by University of Pennsylvania.

Recruiting
Registry status
Early Phase 1
Development phase
90
Enrollment target
2
Study locations

NCT06932809: Recruiting Early Phase 1 study of Tauopathies, sponsored by University of Pennsylvania.

NCT06932809 is a Early Phase 1 study of Tauopathies that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 90 participants, above the 66-participant average among 5 other Tauopathies trials with a reported enrollment target (36% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06932809, a Early Phase 1 study of Tauopathies, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
Early Phase 1
Development phase
90 participants
Enrollment target
2
Study locations

Study Summary

The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 18F-JSS20-183A. The goal of this radiotracer is to quantify 4Repeat Tau (4Rtau) protein that is abnormally deposited in the brain of people with a class of neurodegenerative diseases called tauopathies, such as Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), syndromes of genetic Frontotemporal Lobar Degeneration (genetic FTLD) as well as participants with Parkinson disease (PD), Alzheimer's Disease (AD) and healthy controls. This multicenter project funded by an NIH U19 grant, is centered at U Pennsylvania (Penn, Grant PI: Robert Mach) in collaboration with U Pittsburgh (Pitt), Yale U, U of California at San Francisco (UCSF) and Washington University in St. Louis (WUSTL). The University of Pennsylvania will act as the sIRB for this multi-center human subjects project and participants will be recruited from all sites.

Primary Outcome

Determine biodistribution of the radioactive investigational drug, 18F-JSS20-183A and calculate human dosimetry. A second IV or an arterial line may be placed in the arm contralateral to the side of injection for blood metabolite analysis and/or radioactive counts at various times during the scanning session. Biodistribution, metabolism, excretion and pilot brain uptake data will be collected and human dosimetry will be calculated.

Conditions Studied

Tauopathies

Interventions

  • DIAGNOSTIC_TEST Brain MRI
  • DIAGNOSTIC_TEST Amyloid PET
  • DRUG 18F-JSS20-183A PET
  • BEHAVIORAL Neurological Assessments

Study Locations (2)

California

  • University of California - San Francisco

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2025-05-09
Est. Completion 2030-04
Phase Early Phase 1
University of Pennsylvania

1,423 total trials

What NCT06932809 shows while recruiting

NCT06932809 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, above the 66-participant average among 5 other Tauopathies trials with a reported enrollment target (36% higher).

The record links to 1 condition, with Tauopathies appearing as the primary indexed condition, and to 4 interventions - of which Brain MRI is the first listed.

NCT06932809 reports a single indexed study location in California, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06932809 about?

NCT06932809 is a clinical study titled "Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A". The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 18F-JSS20-183A. The goal of this radiotracer is to quantify 4Repeat Tau (4Rtau) protein that is abnormally deposited in the brain of people with a class of neurodegenerative diseases called tauopathie...

What is the current status of trial NCT06932809?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 90 participants. The study started on 2025-05-09. Estimated completion is 2030-04.

What conditions does trial NCT06932809 study?

This clinical trial studies the following conditions: Tauopathies.

What interventions are being tested in trial NCT06932809?

The interventions under investigation include: Brain MRI (DIAGNOSTIC_TEST), Amyloid PET (DIAGNOSTIC_TEST), 18F-JSS20-183A PET (DRUG), Neurological Assessments (BEHAVIORAL).

Who is sponsoring clinical trial NCT06932809?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06932809 being conducted?

This trial has 2 study locations across California, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Tauopathies

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06932809

Source: ClinicalTrials.gov NCT06932809, the US trial registry maintained by the National Library of Medicine. NCT06932809 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.